Search
SVV-001
go.drugbank.com/drugs/DB06129InvestigationalSVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features.
FINLAY-FR-1
go.drugbank.com/drugs/DB16524ExperimentalFINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373].
Olodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalTreatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous
Vadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[A244165] The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous erythropoiesis-stimulating agents (ESAs), such as [darbepoetin
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalMeropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall ...
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawnOn November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use in the US
Lefradafiban
go.drugbank.com/drugs/DB04863InvestigationalLefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.
LJP 1082
go.drugbank.com/drugs/DB05446ExperimentalAntibody-mediated thrombosis, also called antiphospholipid syndrome (APS), is a blood clotting disorder.
Arotinolol
go.drugbank.com/drugs/DB09204InvestigationalArotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy. Artinolol is being developed by Sumito...